Stem cell therapy for Rheumatoid Arthritis — for patients from United States

If you are researching Rheumatoid Arthritis treatment from the United States, the obstacle is usually access or cost: standard options have plateaued, and regenerative therapy at home runs to €18,400–€46,000. Stem Plus offers the same European GMP standard for a fraction of that — and an easy, mostly visa-free trip.

How Rheumatoid Arthritis is treated

Rheumatoid arthritis is a chronic autoimmune condition where the immune system erroneously attacks joint synovium, causing inflammation, cartilage degradation, and bone erosion. Stem-cell investigations, primarily using placental mesenchymal stem cells, explore whether these cells can modulate the underlying immune dysregulation and reduce synovial inflammation. MSCs secrete immunosuppressive cytokines and may shift macrophage polarisation from pro-inflammatory (M1) to anti-inflammatory (M2) phenotypes. With 43 registered trials and 7 currently recruiting, the therapeutic premise differs from muscular dystrophy: rather than direct tissue regeneration, MSCs aim to suppress the aberrant T-cell and B-cell responses driving the disease. Early clinical data suggest potential for joint-specific injection or systemic administration to reduce disease activity scores and inflammation markers. It is delivered under a physician-led protocol and designed to complement your existing care.

Your cost from United States

Cost ranges are indicative market figures for planning, not quotes.